Replimune
REPL
13.20
-0.05
-0.38%
Replimune
US · REPL
#3130 by market cap
Listed 2018
13.20
-0.05
-0.38%
Live - 5344 symbols - heartbeat 186s ago
· 2026-10-08 04:11
Pre-market
13.20
0.00%
After-hours
13.20
0.00%
- Market cap
- 1.24B
- P/E (TTM)i
- -4.19
- P/Bi
- 11.78
- EPSi
- -3.38
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on REPL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 10.1 percentage points.
Institutional ownership
- Held by institutions
- 104.24% -10.06pp
- Institutions
- 228 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund46.33%
Mutual Fund42.96%
Public Company7.62%
Private Company3.78%
VC/PE Fund3.00%
Individual/Insider1.59%
Insurance Company0.33%
Government Pension Fund0.17%
Top holders as of 2026-08-09
Baker Bros. Advisors LP
11.72% · 11.05M sh
BlackRock
9.51% · 8.96M sh
RTW Investments, LP
7.87% · 7.41M sh
Ridgeback Capital Management LLC
7.76% · 7.31M sh
Montanova Capital, LLC
7.01% · 6.61M sh
State Street Global Advisors
4.71% · 4.44M sh
The Goldman Sachs Group, Inc.
4.63% · 4.36M sh
Boxer Capital Management, LLC
4.23% · 3.98M sh
Vanguard Capital Management, LLC
3.59% · 3.39M sh
Forbion Capital Partners B.V.
2.98% · 2.81M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 11.72% |
| Philip Astley-Sparke | Chief Executive Officer | 1.36% |
| Sushil Patel | Chief Strategy Officer | 0.09% |
| Konstantinos Xynos | Chief Medical Officer | 0.05% |
| Emily Hill | Chief Financial Officer | 0.04% |
| Christopher Sarchi | Chief Commercial Officer | 0.03% |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | 0.02% |
| Joseph Slattery | Independent Director | 0.01% |
| Julian Baker | -- | -- |
| Michael Goller | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-19 | Philip Astley-Sparke | Chief Executive Officer | Other Disposition | -50,000 | -- |
| 2026-08-16 | Emily Hill | Chief Financial Officer | Open Market Disposition | -9,256 | $14.28 |
| 2026-08-10 | Baker Bros. Advisors LP | -- | Open Market Derivative Acquisiti | +2,736,340 | $0.00 |
| 2026-08-09 | Emily Hill | Chief Financial Officer | Open Market Disposition | -11,448 | $12.97 |
| 2026-08-09 | Sushil Patel | Chief Strategy Officer | Open Market Disposition | -39,341 | $12.97 |
| 2026-08-09 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,632 | $12.97 |
| 2026-08-09 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -11,447 | $12.97 |
| 2026-05-31 | Christopher Sarchi | Chief Commercial Officer | Automatic Disposition | -12,000 | $9.24 |
| 2026-05-17 | Philip Astley-Sparke | Chief Executive Officer | Open Market Disposition | -17,657 | $5.08 |
| 2026-05-17 | Emily Hill | Chief Financial Officer | Open Market Disposition | -7,812 | $5.08 |
| 2026-05-17 | Sushil Patel | Chief Strategy Officer | Open Market Disposition | -37,324 | $5.08 |
| 2026-05-17 | Christopher Sarchi | Chief Commercial Officer | Open Market Disposition | -8,626 | $5.08 |
| 2026-05-17 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,894 | $5.08 |
| 2026-05-17 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -14,023 | $5.08 |
| 2026-04-01 | Christopher Sarchi | Chief Commercial Officer | Automatic Disposition | -6,500 | $8.01 |
| 2026-03-31 | Joseph Slattery | Independent Director | Other Derivative Acquisition | +44,500 | $7.61 |
| 2026-03-31 | Julian Baker | -- | Other Derivative Acquisition | +89,000 | $7.61 |
| 2026-03-31 | Philip Astley-Sparke | Chief Executive Officer | Other Acquisition | +50,000 | -- |
| 2026-03-31 | Philip Astley-Sparke | Chief Executive Officer | Other Derivative Acquisition | +75,000 | $7.61 |
| 2026-03-31 | Paolo Pucci | Independent Director | Other Derivative Acquisition | +44,500 | $7.61 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:11:04 · For reference only, not investment advice and not tailored to your situation.